Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

0.7650
+0.02693.64%
Post-market: 0.76990.0049+0.64%19:59 EDT
Volume:3.90M
Turnover:2.99M
Market Cap:223.39M
PE:-3.84
High:0.7800
Open:0.7410
Low:0.7410
Close:0.7381
Loading ...

Ocugen Inc. Stock Rises 6.8%, Outperforms Market

Dow Jones
·
01 Mar

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate Ocu410st for Stargardt Disease

THOMSON REUTERS
·
27 Feb

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

GlobeNewswire
·
27 Feb

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
25 Feb

Ocugen Inc. Stock Falls 7.4%, Underperforms Market

Dow Jones
·
25 Feb

Ocugen Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
22 Feb

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
21 Feb

Ocugen Inc. Stock Rises Tuesday, Outperforms Market

Dow Jones
·
19 Feb

Buy Rating for Ocugen Based on Promising OCU410 Study Progress and Geographic Atrophy Treatment Potential

TIPRANKS
·
15 Feb

Why Ocugen (OCGN) Is Advancing Today

Insider Monkey
·
14 Feb

Ocugen Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
14 Feb

Ocugen Inc. Stock Advances 6.5%, Outperforms Market

Dow Jones
·
14 Feb

Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and Xilio Therapeutics (XLO)

TIPRANKS
·
13 Feb

Ocugen Is Maintained at Buy by Chardan Capital

Dow Jones
·
13 Feb

Ocugen price target raised to $8 from $7 at H.C. Wainwright

TIPRANKS
·
13 Feb

Ocugen Inc - Phase 1/2 Study Shows Favorable Safety Profile for Ocu410

THOMSON REUTERS
·
12 Feb

Ocugen, Inc. Announces Dosing Completion in the Phase 2 Armada Clinical Trial for Ocu410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

THOMSON REUTERS
·
12 Feb

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

GlobeNewswire
·
12 Feb

Ocugen Inc. Stock Falls Tuesday, Underperforms Market

Dow Jones
·
12 Feb

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
11 Feb